Pitolisant hcl CAS: 903576-44-3 is an innovative and promising pharmaceutical product that has gained significant recognition for its potential therapeutic applications. This article aims to shed light on the features, benefits, mechanism, and safety of Pitolisant, along with its competitive landscape, health benefits, potential effects, dosing information, and contraindications.
Chemical Name, Molecular Formula, Formula Weight, and CAS Number:
Pitolisant, also known as BF2.649, is the chemical name for CAS: 903576-44-3. Its molecular formula is C18H20F3N3O3S, and it has a formula weight of 419.43. This unique compound was specifically developed to address certain neurological disorders, with a primary focus on narcolepsy.
Top Ten Keywords and Synonyms:
To provide a broader understanding of Pitolisant, here are its top ten keywords sourced from popular search engines along with their synonyms:
Narcolepsy treatment drug
H3 inverse agonist
Selective histamine 3 receptor antagonist
Sleep-wake cycle regulation
Central nervous system stimulant
Efficacy in cataplexy management
Orphan drug designation
wakefulness promoting agent
Similar Competitive Products:
While Pitolisant stands out as a unique therapeutic option, it's important to mention some similar competitive products available in the market. Notable options include Modafinil, Armodafinil, and Sodium Oxybate. These drugs are also used in the treatment of narcolepsy and have shown efficacy in managing excessive daytime sleepiness.
Pitolisant has shown great promise in promoting wakefulness and improving the sleep-wake cycle, making it an invaluable tool in the management of narcolepsy. Studies have demonstrated its efficacy in reducing excessive daytime sleepiness, cataplexy attacks, and improving overall quality of life for individuals with narcolepsy.
The primary mechanism of action for Pitolisant involves acting as a selective histamine 3 receptor antagonist, thereby increasing the release of histamine. By doing so, Pitolisant enhances wakefulness and alertness. Additionally, it has demonstrated efficacy in reducing the frequency and severity of cataplexy attacks, which are sudden muscular weaknesses triggered by emotions.
Pitolisant's unique mechanism of action lies in its ability to target the histamine H3 receptor, which modulates the release of histamine and other neurotransmitters. By blocking the H3 receptor, Pitolisant increases histamine release, thereby enhancing wakefulness. This mechanism is distinct from other wakefulness-promoting agents, which primarily target the dopamine and norepinephrine systems.
Safety and Side Effects:
In clinical trials, Pitolisant has been generally well-tolerated, with the most common side effects being mild to moderate headache, nausea, anxiety, and insomnia. It is important to consult with a healthcare professional before starting Pitolisant to assess individual suitability and address any concerns regarding potential side effects.
The recommended starting dose of Pitolisant for adults is 9 mg once daily, to be taken orally in the morning. The dose can be gradually increased based on individual response and tolerability, with a maximum daily dose of 36 mg. Dosing adjustments may be needed for individuals with hepatic impairment or those taking certain medications.
Pitolisant should not be used in individuals with severe hepatic impairment or hypersensitivity to the active substance. Additionally, caution should be exercised when combining Pitolisant with other medications, particularly those metabolized by the CYP3A4 enzymes.
Pitolisant CAS: 903576-44-3 is a remarkable pharmaceutical product that has shown great potential in the treatment of narcolepsy and related disorders. With its unique mechanism of action, favorable safety profile, and demonstrated health benefits, Pitolisant represents a significant advancement in the field of sleep medicine. As further research unfolds and more data emerges, the therapeutic applications of Pitolisant may expand, offering new hope and improved quality of life for individuals living with narcolepsy and associated conditions.